Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
Study on the Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD) of the Liver Following Allogeneic Hematopoietic Stem Cell Transplantation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 16 and 65 years
- Received allogeneic hematopoietic stem cell transplantation
- Developed chronic GVHD in the liver after transplantation
- Ineffective prednisone treatment prior to screening
- Received ≤4 lines of systemic therapy prior to screening
- After informed consent, the patient agreed to receive anti-CD25 rhMAb treatment
Exclusion Criteria:
- Elevation of bilirubin, ALT, or alkaline phosphatase due to reasons other than chronic GVHD
- No prior treatment with prednisone
- Overlap syndrome
- Uncontrolled active infection
- Organ failure
- Early progression or recurrence of hematologic diseases
- Allergy to anti-CD25 rhMAb
- Received other interleukin-2 receptor monoclonal antibody treatment due to various reasons within one month after transplantation
- Participated in other clinical studies within one month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Anti-CD25 rhMAb + traditional therapy
|
1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses.
For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
Maintain pre-screening dose
10mg, BID PO
1.25mg/kg, BID PO/IV, target:150-250ng/ml
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall response rate (ORR)
Time Frame: 56 days
|
ORR is defined as the percentage of complete response (CR) and partial response (PR).
|
56 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
duration of response(DOR)
Time Frame: 1 year
|
DOR is defined as the duration calculated from the time of achieving PR or CR until the progression of GVHD, the addition of other systemic immunosuppressive therapy, or death.
|
1 year
|
|
disease-free survival (DFS)
Time Frame: 1 year
|
DFS is defined as the duration of survival after treatment in which the original hematologic disease is in a state of complete remission.
|
1 year
|
|
failure-free survival (FFS)
Time Frame: 1 year
|
Events that are considered as failures include the onset of new chronic GVHD, relapse, and death.
|
1 year
|
|
non-relapse mortality (NRM)
Time Frame: 1 year
|
NRM is defined as death due to reasons other than progression/relapse of hematologic disease.
|
1 year
|
|
overall survival (OS)
Time Frame: 1 year
|
OS is defined as the time from treatment until death from any cause or the last follow-up.
|
1 year
|
|
adverse drug reactions (ADR)
Time Frame: 1 year
|
The occurrence of various organ toxicities related to treatment that emerge following treatment.
|
1 year
|
|
patient-reported outcomes (PRO)
Time Frame: 1 year
|
the unabbreviated scale title is the Lee Chronic GVHD Symptom Scale.the
minimum and maximum are 0 and 100, and higher scores mean a worse outcome.
|
1 year
|
|
Best Overall Response Rate (ORR) of Overall cGVHD
Time Frame: 1 year
|
CR + PR Rate of Overall cGVHD
|
1 year
|
|
Immune Reconstitution
Time Frame: 1 year
|
Humoral immune reconstitution (IgM, IgA, and IgG);Cellular immune reconstitution parameters (CD3⁺, CD4⁺, CD8⁺, and CD19⁺ cell subsets)
|
1 year
|
|
Quality of Life Assessment
Time Frame: 1 year
|
SF-36 Questionnaire;FACT-BMT Questionnaire
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024PHD002-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.